MCL Literature Feed
173 papers on mantle cell lymphoma from PubMed. Updated daily.
This phase 1 study shows the novel chemo-free triplet of magrolimab (anti-CD47), obinutuzumab, and venetoclax is a potential strategy for relapsed/refractory B-cell lymphomas, including MCL.
In Chinese patients with relapsed/refractory MCL previously treated with a covalent BTKi, the non-covalent BTKi pirtobrutinib achieved a 62.9% overall response rate, confirming its global efficacy.
This case report describes therapy-related acute megakaryoblastic leukemia after autologous transplant for MCL, highlighting a rare but severe long-term toxicity of intensive consolidation therapy.
This case series reports uveal melanoma development in patients on BTK inhibitors, suggesting a potential rare but serious toxicity and warranting increased ophthalmologic surveillance for this common MCL therapy.
The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Hemoadsorption with CytoSorb safely reversed severe, refractory cytokine release syndrome in post-CAR-T patients, including one with MCL, offering a potential supportive strategy for managing life-threatening toxicities.
A phase 1 study in Chinese relapsed/refractory B-cell NHL patients establishes the recommended dose of the HDAC inhibitor abexinostat (80 mg BID) with promising activity, supporting further development.
In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.
This preclinical study of a selective immunoproteasome inhibitor in ALL suggests a potential future strategy for MCL to achieve efficacy similar to bortezomib with potentially less off-target toxicity.
In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review provides a practical guide for clinicians on the approved indications and real-world application of anti-CD19 CAR-T cell therapy for mantle cell lymphoma.
The CD20xCD3 bispecific antibody glofitamab induces high and durable complete response rates in heavily pretreated relapsed/refractory MCL, providing a new off-the-shelf immunotherapy option post-BTKi failure.
This case report describes a rare paraneoplastic syndrome in MCL causing severe thrombocytopenia via both bone marrow failure and immune destruction, which responded to lymphoma-directed chemoimmunotherapy but not standard ITP treatment.
This review summarizes the evolution of BTK inhibitors, highlighting how next-generation agents like pirtobrutinib offer improved selectivity, reduced toxicity, and options to overcome resistance in MCL.
This preclinical study reveals bortezomib, unlike carfilzomib, induces unique multi-organelle stress in endothelial cells, providing a specific mechanism for its cardiovascular toxicity relevant to MCL patients.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A new CAR-T hematotoxicity score developed for B-ALL, which replaces ferritin with bone marrow burden, highlights the need to refine existing models like CAR-HT used in MCL for disease-specific prediction.
A case of Candida albicans meningoencephalitis in an MCL patient highlights the diagnostic challenge of CNS symptoms, underscoring the need to consider opportunistic fungal infections beyond CNS relapse.
In a small real-world study of 38 relapsed/refractory MCL patients, zanubrutinib was associated with fewer select adverse events like hypertension and hemorrhage compared to acalabrutinib.
Combining acalabrutinib with bendamustine-rituximab is safe and highly active, achieving a 78% complete response rate and unreached median progression-free survival at 47.6 months in treatment-naive mantle cell lymphoma.
This review highlights using geriatric assessments to guide therapy selection and proactively manage toxicities in older MCL patients, aiming to optimize outcomes and avoid over- or undertreatment.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Brexu-cel CAR-T therapy induced a durable 15-month complete remission in a rapidly progressing, relapsed/refractory MCL patient post-BTKi, highlighting its efficacy despite manageable rare cardiovascular toxicities.
A high-risk, TP53-mutated MCL patient achieved a durable 2-year complete remission with brexucabtagene autoleucel, but developed prolonged severe cytopenias and clonal hematopoiesis, highlighting efficacy and toxicity.
This case report illustrates the efficacy of CAR-T therapy in a relapsed/refractory MCL patient who progressed after both autologous transplant and BTK inhibitor treatment, reinforcing its clinical value.
This modeling study in CLL suggests lower ibrutinib doses (140-280mg) maintain full BTK occupancy, implying potential for dose reduction to manage toxicity in MCL patients without compromising efficacy.
This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
An MCL patient on ibrutinib had persistent COVID-19 missed by nasopharyngeal swabs but diagnosed via bronchoalveolar lavage, underscoring the need for deeper sampling in immunosuppressed patients.
Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.
This review summarizes how second-generation BTK inhibitors like zanubrutinib offer improved target selectivity and tolerability over first-generation agents, providing a potentially safer therapeutic option for MCL patients.
In relapsed/refractory MCL, the phase 3 SYMPATICO trial established ibrutinib plus venetoclax as superior to ibrutinib alone, significantly improving median progression-free survival by nearly 10 months.
This review outlines management strategies for delayed complications of CAR T-cell therapy in MCL, moving beyond acute CRS and ICANS to improve long-term patient care and outcomes.